Document is current
Any future updates will be listed below
-
Authors
Schrage, Ramona
Schmitz, Anna-Lena
Gaffal, Evelyn
Annala, Suvi
Kehraus, Stefan
Wenzel, Daniela
Büllesbach, Katrin M.
Bald, Tobias
Inoue, Asuka
Shinjo, Yuji
Galandrin, Ségolène
Shridhar, Naveen
Hesse, Michael
Grundmann, Manuel
Merten, Nicole
Charpentier, Thomas H.
Martz, Matthew
Butcher, Adrian J.
Slodczyk, Tanja
Armando, Sylvain
Effern, Maike
Namkung, Yoon
Jenkins, Laura
Horn, Velten
Stößel, Anne
Dargatz, Harald
Tietze, Daniel
Imhof, Diana
Galés, Céline
Drewke, Christel
Müller, Christa E.
Hölzel, Michael
Milligan, Graeme
Tobin, Andrew B.
Gomeza, Jesús
Dohlman, Henrik G.
Sondek, John
Harden, T. Kendall
Bouvier, Michel http://orcid.org/0000-0003-1128-0100
Laporte, Stéphane A.
Aoki, Junken
Fleischmann, Bernd K.
Mohr, Klaus
König, Gabriele M.
Tüting, Thomas
Kostenis, Evi
- License Information
-
More Information
Article History
Received: 5 May 2015
Accepted: 6 November 2015
First Online: 14 December 2015
Competing interests
: S.A.L and M.B. belong to the academic consortium ‘Groupe Biosenseurs’ that develop BRET-based G protein activation biosensors, some of which were used in this study. These biosensors are licensed to Domain Therapeutics for commercialization under the trademark BioSens-AllTM. M.B. is the chief executive officer of a not-for-profit company, IRICoR, the misssion of which is to promote the commercial transfer of the technologies of the ‘Institut de Recherche en Immunologie et Cancérologie’. The remaining authors declare no competing financial interests.
